Posted by Michael Wonder on 17 Dec 2016
Grünenthal receives breakthrough therapy designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome, a debilitating orphan disease with high medical need
16 December 2016 - Neridronic acid is the first investigational medicine to receive breakthrough therapy designation for the treatment of complex regional pain syndrome.
Grünenthal and Abiogen Pharma Italy announced today that the U.S. FDA has granted breakthrough therapy designation to neridronic acid, an investigational medicine, for the treatment of complex regional pain syndrome (CRPS), a serious, disabling orphan disease.
Today, with no FDA- or EMA-approved drug treatments, there is a clear need for effective treatment options to address this significant unmet medical need. CRPS is a debilitating condition characterised by severe, continuous, burning pain often occurring in an extremity after injury or surgery. It is one of the most painful conditions a patient can experience.
